Left ventricular hypertrophy (LVH) is a consequence of long-standing hypertension and is considered to be an independent risk factor for cardiovascular morbidity and mortality. Several antihypertensive agents are capable of inducing regression of LVH, but it is not known which class of drugs is most effective. The impact of drug-induced reversal of hypertrophy on ventricular function remains a controversial issue. Furthermore, the long-term clinical benefits of LVH regression have yet to be documented. Controversies also exist regarding the clinical outcomes associated with drug-induced LVH regression.